| Literature DB >> 35209047 |
Beata Morak-Młodawska1, Małgorzata Jeleń1.
Abstract
The lipophilicity parameters (logPcalcd, RM0 and logPTLC) of 10 new active anticancer dipirydothiazines with a 1,2,3-triazole ring were determined theoretically using computational methods and experimentally by reversed-phase TLC. Experimental lipophilicity was assessed using mobile phases (a mixture of TRIS buffer and acetone) using a linear correlation between the RM retention parameter and the volume of acetone. The RM0 parameter was correlated with the specific hydrophobic surface b, revealing two congenerative subgroups: 1,2,3-triazole-1,6-diazaphenothiazines and 1,2,3-triazole-1,8-diazaphenothiazines hybrids. The RM0 parameter was converted into the logPTLC lipophilicity parameter using a calibration curve. The investigated compounds appeared to be moderately lipophilic. Lipophilicity has been compared with molecular descriptors and ADME properties. The new derivatives followed Lipinski's, Ghose's and Veber's rules.Entities:
Keywords: 1,2,3-triazole; Lipinski’s, Ghose’s, Veber’s rules; RP-TLC, ADME properties; anticancer activity; dipyridothiazine; lipophilicity
Mesh:
Substances:
Year: 2022 PMID: 35209047 PMCID: PMC8878114 DOI: 10.3390/molecules27041253
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Influences of lipophilicity on ADME properties and final biological effects.
Figure 2Structure of novel 1,6- and 1,8-diazaphenothiazine with 1,2,3-triazole substituents (1–10) and reference compound prothipendyl (11).
The calculated lipophilic parameters (logPcalcd) for hybdrids of 1,2,3-triazole and dipyridothiazine 1–10 using internet data bases: VCCLAB and SwissADME * [25,27].
| No | Alogps | AC_Logp | ALOGP | MLOGP | XLOGP2 | XLOGP3 | ILogP * | XLogP * | WlogP * | MlogP * | SILICOS-IT * |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 3.22 | 3.21 | 4.43 | 2.42 | 3.71 | 3.17 | 2.61 | 3.17 | 3.30 | 2.76 | 2.64 |
|
| 3.41 | 3.27 | 4.64 | 2.80 | 3.87 | 3.27 | 2.97 | 3.27 | 3.95 | 3.16 | 3.04 |
|
| 3.66 | 3.82 | 5.09 | 2.91 | 4.33 | 3.80 | 3.11 | 3.60 | 4.04 | 3.27 | 3.27 |
|
| 3.32 | 3.02 | 4.31 | 2.08 | 3.44 | 2.89 | 2.94 | 2.89 | 3.20 | 2.13 | 2.66 |
|
| 3.61 | 3.47 | 5.02 | 2.42 | 4.26 | 3.61 | 2.86 | 3.81 | 3.94 | 3.06 | 2.72 |
|
| 3.39 | 3.12 | 3.89 | 2.42 | 3.62 | 2.83 | 2.73 | 2.83 | 3.39 | 2.76 | 2.64 |
|
| 3.30 | 3.18 | 4.10 | 2.80 | 3.78 | 2.94 | 2.83 | 2.94 | 3.95 | 3.16 | 3.04 |
|
| 3.71 | 3.73 | 4.55 | 2.91 | 4.25 | 3.46 | 3.06 | 3.46 | 4.04 | 3.27 | 3.27 |
|
| 3.18 | 2.93 | 3.77 | 2.08 | 3.35 | 2.55 | 2.85 | 2.55 | 3.26 | 2.13 | 2.66 |
|
| 3.49 | 3.38 | 4.48 | 2.42 | 4.17 | 3.27 | 3.16 | 3.27 | 3.88 | 3.06 | 2.72 |
* results obtained using the SwissADME program.
The R0 values and b (slope) and r (correlation coefficient) of the equation R + bC for compounds 1–10.
| No |
|
|
|
|---|---|---|---|
|
| 0.0346 | 2.507 | 0.9946 |
|
| 0.0384 | 2.655 | 0.9951 |
|
| 0.0404 | 2.872 | 0.9932 |
|
| 0.0380 | 2.491 | 0.9981 |
|
| 0.0387 | 2.701 | 0.9946 |
|
| 0.0301 | 1.991 | 0.9908 |
|
| 0.0331 | 2.205 | 0.9925 |
|
| 0.0353 | 2.464 | 0.9885 |
|
| 0.0312 | 1.975 | 0.9895 |
|
| 0.0330 | 2.266 | 0.9899 |
The molecular descriptor and parameters of Lipinski’s, Ghose’s and Veber’s rules for hybdrids of 1,2,3-triazole and dipyridothiazine 1–10 and prothipendyl 11.
| No | Molecular Mass (M) | H-Bond Acceptors | H-Bond Donors | Rotatable Bonds | TPSA | Lipinski’s Rules | Ghose’s Rules | Veber’s Rules |
|---|---|---|---|---|---|---|---|---|
|
| 372 | 4 | 0 | 4 | 85.03 | + | + | + |
|
| 390 | 4 | 0 | 4 | 85.03 | + | + | + |
|
| 406 | 4 | 0 | 4 | 85.03 | + | + | + |
|
| 397 | 5 | 0 | 4 | 108.8 | + | + | + |
|
| 404 | 4 | 0 | 5 | 110.3 | + | + | + |
|
| 372 | 4 | 0 | 4 | 85.03 | + | + | + |
|
| 390 | 4 | 0 | 4 | 85.03 | + | + | + |
|
| 406 | 4 | 0 | 4 | 85.03 | + | + | + |
|
| 397 | 5 | 0 | 4 | 108.8 | + | + | + |
|
| 404 | 4 | 0 | 5 | 110.3 | + | + | + |
|
| 286 | 2 | 0 | 4 | 44.6 | + | + | + |
The ADME activities predicted for 1,2,3-triazole-dipyridothiazine hybdrids 1–10 and prothipendyl 11.
| No | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BBB | 1.2664 | 1.6738 | 2.156 | 0.462 | 0.507 | 0.855 | 1.147 | 1.565 | 0.507 | 0.352 | 3.103 |
| Caco-2 | 26.953 | 29.306 | 51.251 | 22.971 | 57.104 | 24.482 | 26.096 | 50.568 | 57.104 | 56.754 | 22.684 |
| HIA | 98.110 | 98.098 | 97.663 | 99.752 | 99.025 | 98.110 | 98.098 | 97.663 | 99.025 | 99.025 | 97.476 |
| MDCK | 31.186 | 4.540 | 16.317 | 9.067 | 1.787 | 48.877 | 7.323 | 19.818 | 1.787 | 1.930 | 18.983 |
| PPB | 95.034 | 94.700 | 97.370 | 91.793 | 91.234 | 92.088 | 91.670 | 94.175 | 91.234 | 90.008 | 75.453 |
| SP | −3.328 | −3.644 | −3.378 | −3.255 | −3.189 | −3.496 | −3.802 | −3.547 | −3.189 | −3.360 | −3.100 |
The correlation of the R0 values with the molecular descriptors and predicted ADME activities for compounds 1–10.
| No | Molecular Descriptor or ADME Activities | Equation |
|
|---|---|---|---|
|
| M | 0.6791 | |
|
| 0.6892 | ||
|
| TPSA | 0.3265 | |
|
| 0.4452 | ||
|
| BBB | 0.4732 | |
|
| Caco-2 | 0.4732 | |
|
| HIA | 0.5626 | |
|
| MDCK | 0.6172 | |
|
| PPB | 0.6782 | |
|
| SP | 0.3793 |
RM0 and logP values and b (slope) and r (correlation coefficient) of the equation RM = RM0 + bC for standards A–E.
| Parameters | A | B | C | D | E |
|---|---|---|---|---|---|
| log | 1.21 [ | 1.58 [ | 2.43 [ | 3.18 [ | 5.53 [ |
| RM0 | 1.001 | 1.501 | 2.231 | 2.886 | 3.488 |
| − | 0.018 | 0.019 | 0.033 | 0.034 | 0.044 |
| r | 0.9979 | 0.9974 | 0.9960 | 0.9944 | 0.9964 |
The logP values of investigated compounds 1–10.
| No of Compounds | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
| log | 2.668 | 2.814 | 3.027 | 2.652 | 2.859 | 2.159 | 2.369 | 2.625 | 2.142 | 2.429 |
Figure 3Graphical visualization of calculated logP values (using VCCLAB models) of the tested compounds with comparison of logP
Figure 4Graphical visualization of calculated logP values (using SwissADME models) of the tested compounds with comparison of logP * results obtained using the SwissADME program.
Figure 5Graphical visualization of the experimental lipophilicity logP values of the tested 1,6- and 1,8-diazaphenothiazine derivatives compared with the lipophilicity of previously described analogous 2,7- and 3,6-diazaphenothiazines [24]. The indicator * applies to derivatives 2,7-diazaphenothiazine and 3,6-diazaphenothiazine quoted from the publication [24].